J. Goldman & CO LP Aclaris Therapeutics, Inc. Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.56 - $10.95 $521,408 - $870,338	-79,483 Reduced 87.4%	11,456 $78,000
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $717,508 - $967,590	90,939 New	90,939 $943,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $2.18 Million - $3.29 Million	-177,740 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $1.86 Million - $2.61 Million	138,651 Added 354.71%	177,740 $3.2 Million
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $1.81 Million - $3.13 Million	-105,898 Reduced 73.04%	39,089 $686,000
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $585,478 - $2.77 Million	99,911 Added 221.65%	144,987 $3.65 Million
Q4 2020 Feb 16, 2021	SELL	$2.65 - $7.61 $931,273 - $2.67 Million	-351,424 Reduced 88.63%	45,076 $292,000
Q3 2020 Nov 16, 2020	BUY	$1.5 - $2.71 $594,750 - $1.07 Million	396,500 New	396,500 $1.02 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.